• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在缺铁的生理介质中定义 22 种利福霉素对鲍曼不动杆菌、大肠杆菌和肺炎克雷伯菌临床分离株的最小抑菌浓度。

Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates.

机构信息

Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.

Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

PLoS One. 2023 Jun 13;18(6):e0287102. doi: 10.1371/journal.pone.0287102. eCollection 2023.

DOI:10.1371/journal.pone.0287102
PMID:37310985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10263351/
Abstract

Recently, we reported rifabutin hyper-activity against Acinetobacter baumannii. We sought to characterize if any additional rifamycins (n = 22) would also display hyper-activity when tested in iron-limited media against A. baumannii, K. pneumoniae, and E. coli. MICs were determined against representative clinical isolates using the iron-limited media RPMI-1640. Only rifabutin was hyperactive against A. baumannii.

摘要

最近，我们报道了利福布汀对鲍曼不动杆菌的超活性。我们试图研究，如果在缺铁培养基中对鲍曼不动杆菌、肺炎克雷伯菌和大肠杆菌进行测试时，是否还有其他利福霉素（n=22）也会显示出超活性。使用缺铁培养基 RPMI-1640 对代表性临床分离株进行 MIC 测定。只有利福布汀对鲍曼不动杆菌具有超活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/10263351/e599d2e291dc/pone.0287102.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/10263351/9bc5684ddd67/pone.0287102.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/10263351/e599d2e291dc/pone.0287102.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/10263351/9bc5684ddd67/pone.0287102.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bffb/10263351/e599d2e291dc/pone.0287102.g002.jpg

相似文献

1
Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates.在缺铁的生理介质中定义 22 种利福霉素对鲍曼不动杆菌、大肠杆菌和肺炎克雷伯菌临床分离株的最小抑菌浓度。
PLoS One. 2023 Jun 13;18(6):e0287102. doi: 10.1371/journal.pone.0287102. eCollection 2023.
2
Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae.利福布汀和利福平对耐抗生素鲍曼不动杆菌、大肠杆菌、金黄色葡萄球菌、铜绿假单胞菌和肺炎克雷伯菌的活性。
mSphere. 2021 Dec 22;6(6):e0092021. doi: 10.1128/msphere.00920-21. Epub 2021 Nov 24.
3
Geographical patterns of in vitro susceptibilities to tigecycline and colistin among worldwide isolates of Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2021.全球鲍曼不动杆菌、大肠埃希菌和肺炎克雷伯菌分离株对替加环素和黏菌素的体外药敏的地理分布模式：来自 2016-2021 年抗菌药物检测领导和监测（ATLAS）项目的数据。
Int J Antimicrob Agents. 2023 Sep;62(3):106930. doi: 10.1016/j.ijantimicag.2023.106930. Epub 2023 Jul 23.
4
Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.为了将环吡酮胺重新用于治疗耐多药鲍曼不动杆菌、大肠杆菌和肺炎克雷伯菌，我们开展了这项研究。
PLoS One. 2013 Jul 23;8(7):e69646. doi: 10.1371/journal.pone.0069646. Print 2013.
5
[Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].[复方溶葡萄球菌酶消毒剂的抗菌效果及其对大鼠全层皮肤缺损创面植皮后人工真皮感染的预防作用]
Zhonghua Shao Shang Za Zhi. 2018 Apr 20;34(4):225-232. doi: 10.3760/cma.j.issn.1009-2587.2018.04.007.
6
Over expression of AdeABC and AcrAB-TolC efflux systems confers tigecycline resistance in clinical isolates of Acinetobacter baumannii and Klebsiella pneumoniae.AdeABC和AcrAB-TolC外排系统的过表达赋予鲍曼不动杆菌和肺炎克雷伯菌临床分离株对替加环素的耐药性。
Rev Soc Bras Med Trop. 2016 Apr;49(2):165-71. doi: 10.1590/0037-8682-0411-2015.
7
In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.司他夫沙星及其他抗生素对诗琳通公主殿下医学中心、泰国先皇技术学院和三美泰素坤逸医院分离出的细菌的体外活性
J Med Assoc Thai. 2017 Apr;100(4):469-78.
8
In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.体外研究单肟型铁载体 BAL30072 对来自纽约市的当代革兰氏阴性病原体（包括多药耐药株）的活性。
Int J Antimicrob Agents. 2014 Jun;43(6):527-32. doi: 10.1016/j.ijantimicag.2014.02.017. Epub 2014 Apr 13.
9
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.代表性β-内酰胺类药物对肠杆菌科细菌、鲍曼不动杆菌和铜绿假单胞菌的杀菌活性比较
J Antimicrob Chemother. 2022 Apr 27;77(5):1306-1312. doi: 10.1093/jac/dkac026.
10
Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.针对来自MYSTIC监测项目的大肠埃希菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌医院分离株的抗菌药物药效学比较：南美洲2002年OPTAMA项目
Diagn Microbiol Infect Dis. 2004 Jun;49(2):109-16. doi: 10.1016/j.diagmicrobio.2004.03.003.

本文引用的文献

1
Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and Predicts Outcomes in Galleria mellonella.在 RPMI 1640 中进行的抗菌药物敏感性测试显示阿奇霉素对碳青霉烯类耐药鲍曼不动杆菌的疗效，并预测了在大蜡螟中的结果。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0132022. doi: 10.1128/aac.01320-22. Epub 2022 Dec 5.
2
Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae.利福布汀和利福平对耐抗生素鲍曼不动杆菌、大肠杆菌、金黄色葡萄球菌、铜绿假单胞菌和肺炎克雷伯菌的活性。
mSphere. 2021 Dec 22;6(6):e0092021. doi: 10.1128/msphere.00920-21. Epub 2021 Nov 24.
3
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.利福布汀与黏菌素联合用药可降低治疗鲍曼不动杆菌时耐药性的产生。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02204-20.
4
In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.利福布汀对 293 株当代碳青霉烯类耐药鲍曼不动杆菌临床分离株的体外活性及利福布汀作用模式和耐药机制的研究。
J Antimicrob Chemother. 2020 Dec 1;75(12):3552-3562. doi: 10.1093/jac/dkaa370.
5
A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii.营养限制筛选揭示利福布汀对广泛耐药鲍曼不动杆菌的过度活性。
Nat Microbiol. 2020 Sep;5(9):1134-1143. doi: 10.1038/s41564-020-0737-6. Epub 2020 Jun 8.
6
Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.辅助转铁蛋白减少革兰氏阴性菌的抗生素耐药性出现。
J Antimicrob Chemother. 2019 Sep 1;74(9):2631-2639. doi: 10.1093/jac/dkz225.
7
Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.转铁蛋白与环丙沙星联合使用可减缓细菌繁殖、防止耐药性扩增，并提高抗菌方案的效果。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00112-19. Print 2019 May.
8
Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA.外膜蛋白FhuA对一种抗生素利福霉素衍生物的主动转运。
Structure. 2001 Aug;9(8):707-16. doi: 10.1016/s0969-2126(01)00631-1.
9
Active transport of siderophore-mimicking antibacterials across the outer membrane.铁载体模拟抗菌剂跨外膜的主动转运
Drug Resist Updat. 1999 Dec;2(6):363-369. doi: 10.1054/drup.1999.0107.
10
Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli.利福平衍生物通过大肠杆菌中依赖FhuA-TonB的摄取途径高效摄取。
J Gen Microbiol. 1987 Dec;133(12):3505-11. doi: 10.1099/00221287-133-12-3505.